PPCB ▼ -3.8% - Propanc Biopharma, Inc.
$PPCB - Propanc Biopharma Advances Bioanalytical & Immunogenicity Assay Development for Phase 1b First-In-Human Study in up to 50 Advanced Cancer Patients
30-OCT-2026 08:30 AM ET
Share this post
More filings for $PPCB
PPCB ▲ +4.1% - Propanc Biopharma, Inc.Oct 28, 2026PPCB ▼ -3.6% - Propanc Biopharma, Inc.Oct 26, 2026PPCB ▼ -15.6% - Propanc Biopharma, Inc.Oct 22, 2026PPCB ▼ -6.3% - Propanc Biopharma, Inc.Oct 22, 2026PPCB ▲ +5.9% - Propanc Biopharma, Inc.Oct 16, 2026PPCB ▲ +2.4% - Propanc Biopharma, Inc.Oct 14, 2026
View full $PPCB filing history →💬 Comments
Loading comments…
Leave a comment